Skip to main content
. 2021 Jun 8;13:4553–4565. doi: 10.2147/CMAR.S298619

Table 5.

Cox Proportional Hazards Models to Investigate Association of Tertiles of “Healthy Dietary Pattern” and Outcome of Breast Cancer (n=1226)

Tertiles No. of Patients Recurrence Overall Death Death from Breast Cancer
No. of Events HR (95% CI) Ptrend No. of Events HR (95% CI) Ptrend No. of Events HR (95% CI) Ptrend
Unadjusted Model
Tertiles 1 409 61 1 [Reference] 0.41 31 1 [Reference] 0.59 28 1 [Reference] 0.66
Tertiles 2 409 49 0.80 (0.54–1.19) 32 0.99 (0.60–1.63) 29 0.99 (0.59–1.68)
Tertiles 3 408 55 0.85 (0.58–1.26) 35 1.14 (0.70–1.85) 31 1.12 (0.67–1.87)
Model 1
Tertiles 1 409 61 1 [Reference] 0.50 31 1 [Reference] 0.46 28 1 [Reference] 0.67
Tertiles 2 409 49 0.80 (0.54–1.19) 32 1.03 (0.62–1.72) 29 0.96 (0.57–1.63)
Tertiles 3 408 55 0.88 (0.59–1.30) 35 1.20 (0.74–1.96) 31 1.12 (0.67–1.88)
Model 2
Tertiles 1 409 61 1 [Reference] 0.99 31 1 [Reference] 0.20 28 1 [Reference] 0.30
Tertiles 2 409 49 0.86 (0.57–1.30) 32 1.15 (0.68–1.93) 29 1.07 (0.62–1.86)
Tertiles 3 408 55 1.01 (0.64–1.59) 35 1.45 (0.82–2.56) 31 1.37 (0.76–2.49)

Notes: Cox proportional hazards models were used to investigate association of tertiles of dietary patterns and time to outcome. Model 1 were adjusted by age at 18-month follow-up (continuous), stage at diagnosis, ER status, PR status, HER2 status, histology, chemotherapy, radiotherapy and adjuvant hormonal therapy usage at 18-month follow-up. Model 2 were adjusted by age at 18-month follow-up (continuous), total number of comorbidities at 18-month follow-up, stage at diagnosis, ER status, PR status, HER2 status, histology, chemotherapy, radiotherapy, adjuvant hormonal therapy usage at 18-month follow-up, menopausal status at 18-month follow-up, BMI at 18-month follow-up (continuous), level of physical activity at 18-month follow-up (continuous) and total energy intake at 18-month follow-up (continuous).

Abbreviations: HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index.